CMP-Neu5Ac Analogs-based Sialic Acid Glycoengineering

CMP-Neu5Ac Analogs-based Sialic Acid Glycoengineering

Equipped with world-leading technology and professional scientific staff in sialic acid glycoengineering of proteins, CD BioGlyco is fully competent and dedicated to serving as your one-stop service for glycoengineering services.

Biosynthesis of CMP-Neu5Ac

Sialic acid glycoengineering is increasingly applied in the field of glycoscience and beyond. Chemically modified analogs of N-acetylmannosamine, the biological precursor of sialic acid, or sialic acid analogs can be introduced into the metabolic sialic acid biosynthesis pathway resulting in their incorporation into sialoglycans.

The biosynthesis of oligosaccharides, which takes place in the endoplasmic reticulum (ER) and the Golgi apparatus, also employs sugar nucleotides containing pyrophosphate as a leaving group. During the biosynthesis of oligosaccharides undergoing sequential elongation, glycosyltransferases are responsible for the transfer of sugar residues from sugar nucleotides, such as uridine-5'-diphosphate-galactose (UDP-Gal), uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), guanosine-5'-diphosphate-mannose (GDP-Man) and GDP-fucose, to the corresponding oligosaccharyl acceptors through glycosyl linkages. All of these building blocks (Leloir donors) are diphosphate compounds, except for cytidine-5'-monophosphosialic acid (CMP-Neu5Ac). it is activated in the nucleus by the CMP-Neu5Ac synthase (CMP-SA). The biological significance of this unique nuclear localization remains unknown. It is postulated that the negatively charged CMP-Neu5Ac may interact with nuclear proteins involved in gene expression, thereby reducing their binding to DNA. Another hypothesis is that CMP-Neu5Ac binds nuclear proteins, thereby facilitating their transport out of the nucleus when moving to the Golgi apparatus.

Synthesis of CMP-Neu5Ac in the whole cell reaction.Fig.1 Synthesis of CMP-Neu5Ac in the whole cell reaction. (Song, et al., 2003)

CMP-Neu5Ac Analog-based Sialic Acid Glycoengineering Services

CD BioGlyco is proficient at multi-step chemical or enzymatic synthesis and analysis techniques for glycoproteins with different sialic acids. Services we provide include but are not limited to:

  • Production of glycoproteins with different sialic acids according to customer requirements.
  • The samples were pretreated using biological reactions to fluorophores, intracellular esterase deacetylation, and other methods.
  • Chemical modification of cell surface glycans at the N-acyl position.
  • Determination of incorporation and metabolic efficiency of samples using flow cytometry or other techniques.
  • Using radioactivity, mass spectrometry, or HPLC for quantitative analysis of the sialic acids on the modified cell surface, such as CMP-9-azido-Neu5Ac, CMP-9-amino-Neu5Ac, CMP-9-acetamido-Neu5Ac, CMP-9-thioacetamido-Neu5Ac, CMP-9-benzamido-Neu5Ac, CMP-9-fluoresceinyl-Neu5Ac, CMP-9-hexanoylamido-Neu5Ac.

Advantages of Us

  • Highly professional Ph.D. level scientists in glycoengineering
  • Consistently produce glycoproteins with different sialic acid glycosylation on demand
  • Ensuring the amount and purity of glycoprotein delivered
  • Outstanding process development, optimization, and scale-up
  • High stability and consistency of experimental results

CD BioGlyco provides an integrated strategy to study glycoengineering according to each customer's scientific needs. We have various advanced technology to meet your requirements. We are confident to be your essential research assistant in the field of glycoengineering. If you are interested in our services, please contact us for more detailed information.

References:

  1. Kajihara, P.; et al. Unique self-anhydride formation in the degradation of cytidine-5'-monophosphosialic acid (CMP-Neu5Ac) and cytidine-5'-diphosphosialic acid (CDP-Neu5Ac) and its application in CMP-sialic acid analogue synthesis. Chemistry. 2011, 17(27): 7645-7655.
  2. Song, J.; et al. Reassembled biosynthetic pathway for a large-scale synthesis of CMP-Neu5Ac. Marine Drugs. 2003,1(4): 34-45.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.